Thank you BlackDoggie for the greetings and informative reply!
Yes, from January's CC I believe, 7 patients finished the 25 week period and were rolled over. I would assume that translates to them succeeding both endpoints. Can't imagine them wanting to roll over if they had rebounded. I believe around 13 patients were currently screening at that time? Wonder how many of them got in. I do agree with you in that it's important to make sure that every one of the 30 patients has the correct criteria to pass, since such a small N amount means one or two failures has a big impact on the percentage. So that is more important than rapidly enrolling. Which is why I'm still puzzled as to how they can have such a strict criteria for the trial, but I'm assuming it'll be much looser on who can use it when it hits market as a combination therapy. FDA will allow something like this?
You bring up a great point in the uplisting. Is it really that simple in that big institutions can't invest since it's OTC, and once we get uplisted, they'll come pouring in? This stock is very capable of run ups, as we saw last June with the ASM (IIRC?) conference and CROI last month. However, it's obvious that these are quickly battered back down, and the further we dilute, the harder the possible run ups are. Being on this OTC has no support, and any rise results in immediate selling.
News 
Market Data 
Discover 
AI
